Positions
Roswell Park Comprehensive Cancer Center
- Professor of Oncology
- Chair, Pathology and Laboratory Medicine
- Chief of Breast Pathology – Department of Pathology & Laboratory Medicine
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
- Assistant Professor of Pathology & Anatomical Sciences
- Academic Scholar
- Pathology and Anatomical Sciences Department
Background
Education and Training
- MD - University of Damascus, Damascus, Syria
Residency
- University of Damascus, Damascus, Syria
- School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Fellowship
- Roswell Park Cancer Institute,Buffalo, NY
Board Certification
- Anatomic Pathology, American Board of Pathology
- Clinical pathology, American Board of Surgery
Publications
1. Khoury T, Gandhi S, Tozbikian G, Fadare O, Syed S, To B, Quiroga D, Yao S. Attwood K, Yu H. Fang Y. Clinicopathological evaluation of triple-negative breast cancer treated with keynote-522 regimen. Oncologist. 2025 Sep 1;30(9):oyaf231. doi: 10.1093/oncolo/oyaf231. PMID: 40704692
2. Khoury T, Zhan H, Huang X, Ghasemi F, Rajack F, Yuan G, Yu H, Theriot J, Bradiel R, Okamoto K, Ali M. Predicting the Probability of Residual Axillary Nodal Metastases in Patients With Breast Cancer Treated with Neoadjuvant Chemotherapy. Mod Pathol. 2025 Oct 1;38(12):100902. doi: 10.1016/j.modpat.2025.100902. Online ahead of print. PMID: 41043643
3. Alqassim E, Yasmeen S, Etter J, Khoury T. Filling in the Gaps of Examining Human Epidermal Growth Factor Receptor 2 (HER2)-Low and HER2-Ultralow in Breast Cancer: Clone Choice, Sample Size, and Reevaluating Scores Made on Archived Samples. Arch Pathol Lab Med. 2025 Jun 27. doi: 10.5858/arpa.2024-0334-OA. Online ahead of print.PMID: 40577366
4. Khoury T. Interpreting HER2-low at the lower end: Added challenge to the pathologists. Ann Diagn Pathol. 2024 Jun;70:152291. doi: 10.1016/j.anndiagpath.2024.152291. Epub 2024 Mar 7.
PMID: 38471205
5. Khoury T. The Evolving Approach to Breast Cancer: Moving toward De-Escalating Treatment and Personalized Medicine. Cancers (Basel). 2023 Jul 5;15(13):3502. doi: 10.3390/cancers15133502.
PMID: 37444611